GILD
VENTE TOTALE: 53 000 titres (~7 545 867,30 $ US)
- Insiders
- O''Day Daniel Patrick, WELTERS ANTHONY, Bluestone Jeffrey
- Total bought
- —
- Total sold
- $7,545,867
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bullish signal Scored 2026-09-04
GILD presents a compelling combination of strong financial recovery (net margin 28.9%, healthy ROE/ROIC) and a meaningful earnings catalyst backed by the recent FDA approval of Bixlenvo and analyst upgrades to Strong…
The first sentence of the analysis written for GILD on 2026-09-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | |
| Ebit Margin | 36.8% | 5.8% | 28.8% | 24.7% | 34.0% | |
| Ebitda Margin | 46.1% | 15.4% | 38.7% | 32.4% | 41.5% | |
| Operating Profit Margin | 39.7% | 5.8% | 28.0% | 26.9% | 36.3% | |
| Pretax Profit Margin | 33.3% | 2.4% | 25.3% | 21.3% | 30.3% | |
| Continuous Operations Profit Margin | 28.9% | 1.7% | 20.7% | 16.7% | 22.7% | |
| Net Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Bottom Line Profit Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | |
| Current Ratio | 1.553 | 1.597 | 1.426 | 1.285 | 1.272 | |
| Quick Ratio | 1.403 | 1.455 | 1.268 | 1.151 | 1.133 | |
| Solvency Ratio | 0.310 | 0.082 | 0.212 | 0.160 | 0.176 | |
| Cash Ratio | 0.640 | 0.832 | 0.539 | 0.482 | 0.460 | |
| Price To Earnings Ratio | 17.944 | 243.079 | 17.844 | 23.456 | 14.639 | |
| Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Forward Price To Earnings Growth Ratio | 0.011 | -2.653 | 0.742 | -0.895 | 0.003 | |
| Price To Earnings Diluted Ratio | 18.103 | 243.079 | 18.002 | 23.585 | 14.728 | |
| Price To Earnings Diluted Growth Ratio | 0.011 | -2.655 | 0.762 | -0.901 | 0.003 | |
| Price To Book Ratio | 6.726 | 5.959 | 4.428 | 5.073 | 4.329 | |
| Price To Sales Ratio | 5.186 | 4.006 | 3.728 | 3.949 | 3.340 | |
| Price To Free Cash Flow Ratio | 16.147 | 11.178 | 13.624 | 12.912 | 8.440 | |
| Price To Operating Cash Flow Ratio | 15.240 | 10.638 | 12.628 | 11.876 | 8.011 | |
| Debt To Assets Ratio | 0.422 | 0.453 | 0.402 | 0.399 | 0.393 | |
| Debt To Equity Ratio | 1.098 | 1.382 | 1.094 | 1.188 | 1.267 | |
| Debt To Capital Ratio | 0.523 | 0.580 | 0.523 | 0.543 | 0.559 | |
| Long Term Debt To Capital Ratio | 0.494 | 0.563 | 0.504 | 0.519 | 0.544 | |
| Financial Leverage Ratio | 2.600 | 3.052 | 2.721 | 2.974 | 3.225 | |
| Working Capital Turnover Ratio | 4.299 | 4.803 | 6.771 | 8.569 | 7.036 | |
| Operating Cash Flow Ratio | 0.848 | 0.902 | 0.710 | 0.807 | 0.981 | |
| Operating Cash Flow Sales Ratio | 0.340 | 0.377 | 0.295 | 0.333 | 0.417 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | 0.952 | 0.927 | 0.920 | 0.949 | |
| Debt Service Coverage Ratio | 3.209 | 1.513 | 3.373 | 2.370 | 3.676 | |
| Interest Coverage Ratio | 11.427 | 1.701 | 8.056 | 7.840 | 9.908 | |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | 5.966 | 4.453 | 3.991 | 7.509 | |
| Operating Cash Flow Coverage Ratio | 0.402 | 0.405 | 0.320 | 0.360 | 0.426 | |
| Capital Expenditure Coverage Ratio | 17.796 | 20.704 | 13.685 | 12.462 | 19.661 | |
| Dividend Paid And Capex Coverage Ratio | 2.194 | 2.438 | 1.822 | 2.045 | 2.721 | |
| Dividend Payout Ratio | 0.470 | 8.162 | 0.672 | 0.808 | 0.579 | |
| Enterprise Value Multiple | 12.523 | 29.749 | 11.433 | 14.410 | 9.935 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.8% | ▲0.6% | ▲1.2% |
| Ebit Margin | 36.8% | ▲30.9% | ▲10.7% |
| Ebitda Margin | 46.1% | ▲30.7% | ▲11.3% |
| Operating Profit Margin | 39.7% | ▲34.0% | ▲12.4% |
| Pretax Profit Margin | 33.3% | ▲30.9% | ▲10.8% |
| Continuous Operations Profit Margin | 28.9% | ▲27.2% | ▲10.8% |
| Net Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Bottom Line Profit Margin | 28.9% | ▲27.2% | ▲10.7% |
| Current Ratio | 1.553 | ▼-0.044 | ▲0.126 |
| Quick Ratio | 1.403 | ▼-0.052 | ▲0.121 |
| Solvency Ratio | 0.310 | ▲0.228 | ▲0.122 |
| Cash Ratio | 0.640 | ▼-0.192 | ▲0.050 |
| Price To Earnings Ratio | 17.944 | ▼-225.135 | ▼-45.448 |
| Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Forward Price To Earnings Growth Ratio | 0.011 | ▲2.663 | ▲0.569 |
| Price To Earnings Diluted Ratio | 18.103 | ▼-224.976 | ▼-45.396 |
| Price To Earnings Diluted Growth Ratio | 0.011 | ▲2.666 | ▲0.567 |
| Price To Book Ratio | 6.726 | ▲0.767 | ▲1.423 |
| Price To Sales Ratio | 5.186 | ▲1.180 | ▲1.144 |
| Price To Free Cash Flow Ratio | 16.147 | ▲4.970 | ▲3.687 |
| Price To Operating Cash Flow Ratio | 15.240 | ▲4.602 | ▲3.561 |
| Debt To Assets Ratio | 0.422 | ▼-0.030 | ▲0.009 |
| Debt To Equity Ratio | 1.098 | ▼-0.283 | ▼-0.107 |
| Debt To Capital Ratio | 0.523 | ▼-0.057 | ▼-0.022 |
| Long Term Debt To Capital Ratio | 0.494 | ▼-0.069 | ▼-0.031 |
| Financial Leverage Ratio | 2.600 | ▼-0.452 | ▼-0.315 |
| Working Capital Turnover Ratio | 4.299 | ▼-0.504 | ▼-1.997 |
| Operating Cash Flow Ratio | 0.848 | ▼-0.054 | ▼-0.001 |
| Operating Cash Flow Sales Ratio | 0.340 | ▼-0.036 | ▼-0.012 |
| Free Cash Flow Operating Cash Flow Ratio | 0.944 | ▼-0.008 | ▲0.005 |
| Debt Service Coverage Ratio | 3.209 | ▲1.696 | ▲0.381 |
| Interest Coverage Ratio | 11.427 | ▲9.726 | ▲3.640 |
| Short Term Operating Cash Flow Coverage Ratio | 3.569 | ▼-2.397 | ▼-1.528 |
| Operating Cash Flow Coverage Ratio | 0.402 | ▼-0.004 | ▲0.019 |
| Capital Expenditure Coverage Ratio | 17.796 | ▼-2.908 | ▲0.934 |
| Dividend Paid And Capex Coverage Ratio | 2.194 | ▼-0.244 | ▼-0.050 |
| Dividend Payout Ratio | 0.470 | ▼-7.692 | ▼-1.668 |
| Enterprise Value Multiple | 12.523 | ▼-17.226 | ▼-3.087 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $152.69B | $115.19B | $101.10B | $107.74B | $91.20B | |
| Enterprise value | $170.06B | $131.91B | $120.00B | $127.56B | $112.56B | |
| EV / Sales | 5.78x | 4.59x | 4.43x | 4.68x | 4.12x | |
| EV / Op. cash flow | 16.97x | 12.18x | 14.99x | 14.06x | 9.89x | |
| EV / Free cash flow | 17.98x | 12.80x | 16.17x | 15.29x | 10.42x | |
| EV / EBITDA | 12.52x | 29.75x | 11.43x | 14.41x | 9.94x | |
| Net debt / EBITDA | 1.28x | 3.77x | 1.80x | 2.24x | 1.89x | |
| Current ratio | 1.55x | 1.60x | 1.43x | 1.28x | 1.27x | |
| Income quality | 1.18x | 22.56x | 1.41x | 1.98x | 1.84x | |
| Graham number | $53 | $12 | $43 | $37 | $43 | |
| Graham net-net | -$18 | -$19 | -$22 | -$25 | -$29 | |
| Tax burden | 86.9% | 69.6% | 82.6% | 79.0% | 75.2% | |
| Interest burden | 90.5% | 41.4% | 87.9% | 86.1% | 89.2% | |
| Working capital | $6.53B | $7.17B | $4.80B | $3.21B | $3.16B | |
| Invested capital | $37.43B | $40.84B | $44.89B | $45.89B | $50.07B | |
| Return on assets | 14.4% | 0.8% | 9.1% | 7.3% | 9.2% | |
| Operating ROA | 19.8% | 2.7% | 12.1% | 11.2% | 14.5% | |
| Return on tangible assets | 25.2% | 1.6% | 20.7% | 17.7% | 23.8% | |
| Return on equity | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | |
| Return on invested capital | 20.3% | 2.4% | 11.8% | 10.6% | 12.8% | |
| Return on capital employed | 24.8% | 3.5% | 15.0% | 14.1% | 17.6% | |
| Earnings yield | 5.6% | 0.4% | 5.6% | 4.3% | 6.8% | |
| Free cash flow yield | 6.2% | 8.9% | 7.3% | 7.7% | 11.8% | |
| Capex / Op. cash flow | 5.6% | 4.8% | 7.3% | 8.0% | 5.1% | |
| Capex / Depreciation | 20.4% | 18.9% | 21.7% | 34.6% | 28.2% | |
| Capex / Sales | 1.9% | 1.8% | 2.2% | 2.7% | 2.1% | |
| SG&A / Sales | 19.4% | 21.2% | 22.5% | 20.8% | 19.2% | |
| R&D / Sales | 19.7% | 20.5% | 21.1% | 18.2% | 16.9% | |
| Stock comp / Sales | 3.0% | 2.9% | 2.8% | 2.4% | 2.3% | |
| Intangibles / Total assets | 42.9% | 47.9% | 56.0% | 58.9% | 61.5% | |
| Days sales outstanding | 61d | 56d | 63d | 64d | 60d | |
| Days payables outstanding | 42d | 49d | 31d | 58d | 39d | |
| Operating cycle | 165d | 156d | 163d | 161d | 150d | |
| Cash conversion cycle | 123d | 107d | 132d | 103d | 111d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+32.6%EV / Sales ▲+25.9%EV / EBITDA ▼-57.9%EV / Op. cash flow ▲+4.792Earnings yield ▲+0.052Graham number ▲+41.412
Profitability
Return on equity ▲+0.350Return on assets ▲+0.136Return on invested capital ▲+0.180Return on capital employed ▲+0.212Operating ROA ▲+0.171Income quality ▼-21.381Tax burden ▲+0.173
Efficiency
Days sales outstanding ▲+4.801Days payables outstanding ▼-6.776Operating cycle ▲+8.820Cash conversion cycle ▲+15.596Capex / Sales ▲+0.001R&D / Sales ▼-0.008
Balance-sheet strength
Current ratio ▼-0.045Net debt / EBITDA ▼-2.492Working capital ▼-640000000.000Invested capital ▼-3418000000.000Intangibles / Total assets ▼-0.051
Change over 5 years
Valuation
Market cap ▲+67.4%EV / Sales ▲+40.1%EV / EBITDA ▲+26.0%EV / Op. cash flow ▲+7.087Earnings yield ▼-0.013Graham number ▲+9.748
Profitability
Return on equity ▲+0.079Return on assets ▲+0.053Return on invested capital ▲+0.075Return on capital employed ▲+0.072Operating ROA ▲+0.053Income quality ▼-0.659Tax burden ▲+0.117
Efficiency
Days sales outstanding ▲+0.847Days payables outstanding ▲+2.880Operating cycle ▲+15.248Cash conversion cycle ▲+12.368Capex / Sales ▼-0.002R&D / Sales ▲+0.028
Balance-sheet strength
Current ratio ▲+0.280Net debt / EBITDA ▼-0.606Working capital ▲+3367000000.000Invested capital ▼-12643000000.000Intangibles / Total assets ▼-0.186
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-07 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-05-06 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2026-01-27 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-06-06 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-14 | Josh S. Gottheimer | Sale | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-03-31 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-03-10 | Carol Devine Miller | Purchase | $1,001 - $15,000 |
| 2025-03-07 | Josh S. Gottheimer | Purchase | $1,001 - $15,000 |
| 2024-12-24 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-03-25 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-02-13 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale | $15,001 - $50,000 |
| 2023-05-25 | Zoe Lofgren | Sale | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Purchase | $15,001 - $50,000 |
| 2022-09-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-09-09 | Zoe Lofgren | Purchase | $1,001 - $15,000 |
| 2022-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-08-01 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-04-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-01-20 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2021-11-10 | Carol Devine Miller | Sale (Partial) | $15,001 - $50,000 |
| 2021-04-09 | Sara Jacobs | Sale (Full) | $15,001 - $50,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-02-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-01-21 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2020-12-22 | Gilbert Ray Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2020-12-18 | Dean Phillips | Sale (Partial) | $1,001 - $15,000 |
| 2020-09-23 | Dean Phillips | Purchase | $1,001 - $15,000 |
| 2020-09-01 | Ed Perlmutter | Sale (Partial) | $1,001 - $15,000 |
| 2020-07-15 | Ed Perlmutter | Purchase | $1,001 - $15,000 |
| 2020-07-08 | Roger Wayne Marshall | Sale (Full) | $1,001 - $15,000 |
| 2020-06-29 | William R. Timmons | Sale (Full) | $1,001 - $15,000 |
| 2020-05-07 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-05 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-05-04 | Roger Wayne Marshall | Purchase | $1,001 - $15,000 |
| 2020-03-18 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-02-20 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2020-02-07 | Gilbert Ray Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-21 | Mikie Sherrill | Purchase | $1,001 - $15,000 |
| 2019-12-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
| 2019-10-25 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2019-09-19 | Bill Flores | Purchase | $1,001 - $15,000 |
| 2019-04-18 | Mikie Sherrill | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-09-05 Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play? Gilead is best known for its dominant HIV franchise. But the company has been actively diversifying via acquisitions.
- 2026-09-04 Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? Gilead''s quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.
- 2026-09-03 Why Is Gilead (GILD) Up 13.6% Since Last Earnings Report? Gilead (GILD) reported earnings 30 days ago. What''s next for the stock?
- 2026-09-01 Can Bixlenvo Unlock New Growth for Gilead''s HIV Business? GILD''s FDA approval of Bixlenvo expands its HIV portfolio with a first-of-its-kind single-tablet option for underserved patients.
- 2026-09-01 Gilead (GILD) Upgraded to Strong Buy: What Does It Mean for the Stock? Gilead (GILD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 2026-09-01 Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest? When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock''s price, but are they really important?
- 2026-08-29 Archer Investment Corp Takes Position in Gilead Sciences, Inc. $GILD Archer Investment Corp acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,578 shares of the biopharmaceutical company''s stock, valued at approximately $957,000. A number of other hedge funds
- 2026-08-29 BNP Paribas Purchases 20,329 Shares of Gilead Sciences, Inc. $GILD BNP Paribas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 20.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 118,671 shares of the biopharmaceutical company''s stock after buying an additional 20,329 shares during the period. BNP Paribas''
- 2026-08-29 Beacon Pointe Advisors LLC Reduces Holdings in Gilead Sciences, Inc. $GILD Beacon Pointe Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 25.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 66,695 shares of the biopharmaceutical company''s stock after selling 23,036 shares during the period. Beacon
- 2026-08-28 Gilead Wins FDA Nod for Bixlenvo in Adults Living With HIV Infection GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet option for patients on complex therapies.